Investor Relations
AMS at a Glance
Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.
Our primary focus is to create quality outcomes for our:
- Customers
- Patients
- Shareholders
Financial Calendar
Full Year Period End
31 December 2020Interim Results Announcement
September 2020 (TBC)Half Year Period End
30 June 2020Final Dividend Payment
19 June 2020Annual General Meeting
10 June 2020 (Closed Meeting)Preliminary Results Announcement
11 March 2020Financial Reports
2019 Annual Report
May 2020Notice of AGM
May 20202019 Interim Report
September 20192018 Annual Report
April 20192018 Interim Report
September 20182017 Annual Report
April 20182017 Interim Report
September 20172016 Annual Report
April 20172016 Interim Report
September 20162015 Annual Report
April 20162015 Interim Report
October 20152014 Annual Report
April 20152014 Interim Report
September 20142013 Annual Report
April 2014News
Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More
AMS attended the Stifel UK Healthcare Seminar on 5 December 2019. Read More
Latest Financial Highlights
Summary
Whilst 2019 proved a challenging year for the Group, with the downturn of US LiquiBand® and the third-party sterilisation failure at the end of 2019 which was resolved in early 2020, we are pleased to report good growth in other areas of the business enabled the Group to deliver revenues of £102.4 million, broadly in line with 2018.
Adjusted profit before tax decreased by 7% to £26.6 million due to our operational investment in Sealantis, adverse sales mix and currency contracts. This contributed to a decrease of 8% in adjusted diluted earnings per share.
The Surgical Business Unit sales were restricted by US LiquiBand® performance, resulting in a 1% decrease in revenue to £56.5 million and by 2% at constant currency. We have made progress on the two key product approvals needed to support the recovery of LiquiBand® in the US. LiquiBand® Rapid™ was recently approved by the FDA and the LiquiBand® XL pilot clinical study is in progress and will be concluded by the end of Q1 2020.
Our Woundcare business grew 1% to £45.8 million but was flat at constant currency. We strengthened our woundcare portfolio in the year with US approvals for our antimicrobial PHMB foam and silver high-performance dressings, both of which were signed to partners and launched to the market in Q4 2019.
The acquisition of Biomatlante demonstrates our strategy of utilising our strong cash position to acquire businesses with complementary products, exciting technologies and new routes to market and the acquisition of Sealantis demonstrates our willingness to invest in longer term growth opportunities.